公开(公告)号：US20190250145A1

公开(公告)日：2019-08-15

申请号：US16228433

申请日：2018-12-20

申请人： THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK

发明人： Steven Marx ,  Alexander Kushnir ,  Lin Yang ,  Alex Katchman ,  Henry M. Colecraft

IPC分类号： G01N33/50 ,  A61K31/4422 ,  A61P9/00

CPC分类号： G01N33/5041 ,  A61K31/4422 ,  A61P9/00

摘要： The present invention provides, inter alia, methods for identifying a candidate agent that can treat or ameliorate the effects of a heart condition caused by the effects of abnormal beta-adrenergic receptor activation on calcium levels in cardiomyocytes in a subject. Compositions that include the candidate agents identified by the methods disclosed, and methods of treating or ameliorating the effects of a heart condition in a subject by administering to the subject the candidate agents identified by the methods disclosed, are also provided.

公开(公告)号：US20190216899A1

公开(公告)日：2019-07-18

申请号：US16275120

申请日：2019-02-13

申请人： Tulavi Therapeutics, Inc.

发明人： Corinne Bright

IPC分类号： A61K38/21 ,  A61N5/02 ,  A61K9/06 ,  A61B18/18 ,  A61K31/4422 ,  A61K31/475 ,  A61K31/55 ,  A61B17/34 ,  A61K47/10 ,  A61K45/06 ,  A61B18/14 ,  A61L31/14 ,  A61L31/06 ,  A61L27/56 ,  A61L27/52 ,  A61L27/18 ,  A61B8/12 ,  A61N7/02 ,  A61K31/337 ,  A61K31/19 ,  A61K31/045 ,  A61K9/51 ,  A61K47/36 ,  A61B90/30

CPC分类号： A61K38/217 ,  A61B8/0808 ,  A61B8/12 ,  A61B17/3401 ,  A61B17/3403 ,  A61B18/1492 ,  A61B18/1815 ,  A61B90/30 ,  A61B2017/3413 ,  A61B2018/00434 ,  A61B2018/0044 ,  A61B2018/1861 ,  A61B2018/1869 ,  A61K9/06 ,  A61K9/5161 ,  A61K31/045 ,  A61K31/19 ,  A61K31/337 ,  A61K31/4422 ,  A61K31/475 ,  A61K31/55 ,  A61K45/06 ,  A61K47/10 ,  A61K47/36 ,  A61L27/18 ,  A61L27/52 ,  A61L27/56 ,  A61L31/06 ,  A61L31/145 ,  A61L31/146 ,  A61L2400/06 ,  A61N5/022 ,  A61N7/022 ,  A61N2007/0021 ,  C08L71/02

摘要： Methods, devices and systems are described for decreasing the activity of the sympathetic nervous innervation to and from the lungs and the vessels supplying the lungs to treat pulmonary medical conditions such as asthma. In one embodiment, the method may involve advancing an intravascular instrument to a target location in a blood vessel within the intercostal vasculature to ablate either or both the sympathetic afferent and efferent nerves lying within the paravertebral gutter including the visceral fibers that travel to the cardiothoracic cavity and abdominopelvic viscera and the T1 to T4/5 sympathetic chain. In another embodiment, an intravascular instrument may be advanced to the bronchial vessels to ablate either or both the sympathetic afferent and efferent nerves in and around the posterior pulmonary plexus. In one embodiment the ablative agent is a neurolytic agent delivered in a gel. This approach may be utilized to treat other cardiac and pulmonary diseases.

公开(公告)号：US20190183844A1

公开(公告)日：2019-06-20

申请号：US16219064

申请日：2018-12-13

申请人： Genzyme Corporation

发明人： Jing LI ,  M. Judith PETERSCHMITT ,  Vanaja KANAMALURU ,  Jun CHEN ,  Sebastiaan J.M. GAEMERS ,  Dan RUDIN

IPC分类号： A61K31/343 ,  A61P1/16 ,  A61P13/12

CPC分类号： A61K31/343 ,  A61K31/138 ,  A61K31/15 ,  A61K31/381 ,  A61K31/4025 ,  A61K31/427 ,  A61K31/4422 ,  A61K31/496 ,  A61K45/06 ,  A61P1/16 ,  A61P3/00 ,  A61P13/12 ,  A61K2300/00

摘要： Methods for treating Gaucher disease in patients with renal or hepatic impairment.

公开(公告)号：US20190183794A1

公开(公告)日：2019-06-20

申请号：US16155612

申请日：2018-10-09

申请人： RxOMEG Therapeutics LLC

发明人： Indu Muni ,  Naomi Vishnupad

IPC分类号： A61K9/08 ,  A61K31/4422 ,  A61P29/00 ,  A61P19/02 ,  A61K31/496 ,  A61P31/00 ,  A61K31/403 ,  A61K31/165 ,  A61K9/00 ,  A61K31/4709

CPC分类号： A61K9/08 ,  A61K9/0053 ,  A61K9/0095 ,  A61K31/165 ,  A61K31/403 ,  A61K31/4422 ,  A61K31/4709 ,  A61K31/496 ,  A61K47/02 ,  A61K47/10 ,  A61K47/12 ,  A61K47/26 ,  A61K47/36 ,  A61P19/02 ,  A61P29/00 ,  A61P31/00

摘要： The use of oral colchicine solutions in combination with other therapeutics, while minimizing toxic drug to drug interactions are described herein. Related compositions are also provided.

公开(公告)号：US20190008723A1

公开(公告)日：2019-01-10

申请号：US16131986

申请日：2018-09-14

申请人： MEDISCA PHARMACEUTIQUE INC.

发明人： Panagiota Danopoulos ,  Vargha Talebi

IPC分类号： A61J1/05 ,  A61K31/57 ,  A61K47/42 ,  A61K31/4458 ,  A61K47/26 ,  A61K47/38 ,  A61K31/196 ,  A61K31/192 ,  A61K31/4418 ,  A61K9/00 ,  A61K31/565 ,  A61K31/7048 ,  A61K33/14 ,  A61K31/045 ,  A61K31/197 ,  A61K47/10 ,  A61K9/06 ,  A61K47/46 ,  A61K9/107 ,  B65B7/16 ,  A61J3/04 ,  B01F11/00 ,  A61K31/137 ,  A61K31/135 ,  A61K31/195 ,  A61K31/351 ,  A61K31/4422 ,  A61K31/445

CPC分类号： A61J1/05 ,  A61J3/04 ,  A61K9/0034 ,  A61K9/06 ,  A61K9/107 ,  A61K31/045 ,  A61K31/135 ,  A61K31/137 ,  A61K31/192 ,  A61K31/195 ,  A61K31/196 ,  A61K31/197 ,  A61K31/351 ,  A61K31/4418 ,  A61K31/4422 ,  A61K31/445 ,  A61K31/4458 ,  A61K31/565 ,  A61K31/57 ,  A61K31/7048 ,  A61K33/14 ,  A61K47/10 ,  A61K47/26 ,  A61K47/38 ,  A61K47/42 ,  A61K47/46 ,  B01F9/0001 ,  B01F9/0018 ,  B01F9/0032 ,  B01F9/0034 ,  B01F11/00 ,  B01F15/00253 ,  B01F15/0074 ,  B01F2009/0085 ,  B65B7/16 ,  A61K2300/00

摘要： The present disclosure relates to a container assembly for use in a planetary mixer, which may comprise a jar with an inner wall, an adapter in contact with the inner wall of the jar, a metered-dosage dispenser having a tubular body, and a lid attachable to an rim of the jar, wherein the adapter, if included, may be configured to clamp to the metered-dosage dispenser, if included, and the adapter, if included, may be further configured to keep the metered-dosage dispenser away from the inner wall of the jar, wherein at least a portion of the metered-dosage dispenser, if included, may be configured to allow visibility of at least some contents inside the body of the metered-dosage dispenser from outside the body of the metered-dosage dispenser, and wherein the body of the metered-dosage dispenser, if included, may have a height-to-base ratio (HBR) between 0.75 and 1.5 at half volume.

公开(公告)号：US20190000812A1

公开(公告)日：2019-01-03

申请号：US16066921

申请日：2017-01-04

申请人： ObsEva S.A.

发明人： Patrick Naxos PAGE ,  Matthias SCHWARZ ,  Catherine JORAND-LEBRUN ,  Anna QUATTROPANI ,  Vincent POMEL ,  Ernest LOUMAYE ,  Oliver POHL ,  Jean-Pierre GOTTELAND

IPC分类号： A61K31/426 ,  A61K9/00 ,  A61K45/06 ,  A61P15/06

CPC分类号： A61K31/426 ,  A61K9/0019 ,  A61K9/0053 ,  A61K9/0095 ,  A61K9/16 ,  A61K9/20 ,  A61K9/48 ,  A61K31/40 ,  A61K31/4422 ,  A61K38/095 ,  A61K45/06 ,  A61P15/06 ,  A61K2300/00

摘要： The invention provides pharmaceutical compositions comprising a compound of formula (I) or (II) and an additional therapeutic agent Also provided is the HCI salt and crystalline form of the compound of formula (I). The compounds inhibit the prostaglandin F receptor (PGF2alpha) and thus useful in the treatment of disorders such as preterm labor at the early gestational stage.

公开(公告)号：US20180185346A1

公开(公告)日：2018-07-05

申请号：US15740776

申请日：2015-06-30

申请人： SHANGHAI JIAO TONG UNIVERSITY

发明人： Yongyong SHI ,  Zhijian SONG

IPC分类号： A61K31/4422 ,  A61P35/00

CPC分类号： A61K31/4422 ,  A61P35/00

摘要： This invention discloses uses for nicardipine in preparing anti-lung cancer products. This invention provides uses for nicardipine in the preparation of products to treat non-small cell lung cancer. From carrying out cancer drug repositioning for the FDA- and CFDA-approved drug nicardipine, experiments for this invention show, based on screening of non-anti-cancer drugs for various cancer cell lines (tissue types) and mutation sites, that nicardipine has a new use as an anti-small cell lung cancer and/or anti-non small cell lung cancer medication, thus achieving a new purpose for an old drug.

公开(公告)号：US09993432B2

公开(公告)日：2018-06-12

申请号：US13130294

申请日：2009-11-19

申请人： Alexander Kuhl ,  Erich Brendel ,  Frank Bröcker ,  Adrian Funke ,  Andreas Ohm ,  Dennis Kvesic ,  Thomas Volkmer

发明人： Alexander Kuhl ,  Erich Brendel ,  Frank Bröcker ,  Adrian Funke ,  Andreas Ohm ,  Dennis Kvesic ,  Thomas Volkmer

IPC分类号： A61K9/20 ,  A61K9/48 ,  A61K9/24 ,  A61K31/4422 ,  A61K9/00 ,  A61K9/28 ,  A61K31/4178 ,  A61K31/4184 ,  A61K45/06

CPC分类号： A61K9/2031 ,  A61K9/0004 ,  A61K9/2072 ,  A61K9/2086 ,  A61K9/209 ,  A61K9/2853 ,  A61K9/2866 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/4422 ,  A61K45/06 ,  A61K2300/00

摘要： The present invention relates to a pharmaceutical dosage form comprising an active ingredient combination of nifedipine or nisoldipine and at least one angiotensin II antagonist and/or at least one diuretic, characterized in that nifedipine or nisoldipine is released in the body in a controlled (modified) manner and the angiotensin II antagonist and/or the diuretic is released rapidly (immediate release (IR)), and also to processes for their preparation, to their use as medicaments and to their use for the prophylaxis, secondary prophylaxis or treatment of disorders.

公开(公告)号：US09968675B2

公开(公告)日：2018-05-15

申请号：US15622428

申请日：2017-06-14

申请人： Biocrine AB

发明人： Per Olof Berggren

IPC分类号： C12N5/00 ,  A61K39/395 ,  A61K31/713 ,  A61K31/7088 ,  A61K31/455 ,  A61K31/554 ,  A61K31/277 ,  A61K31/4422 ,  A61K31/7105 ,  A61K45/06 ,  G01N33/68

CPC分类号： A61K39/3955 ,  A61K31/277 ,  A61K31/4422 ,  A61K31/455 ,  A61K31/554 ,  A61K31/7088 ,  A61K31/7105 ,  A61K31/713 ,  A61K39/395 ,  A61K45/06 ,  G01N33/6854 ,  G01N2800/042 ,  G01N2800/28 ,  G01N2800/50

摘要： Methods for treating and/or limiting development of diabetes in a subject with amyotrophic lateral sclerosis (ALS) by inhibiting IgG-mediated activation of voltage-gated calcium channels (VGCCs) in cells of the subject, by one or more of removing IgG from blood of the subject, blocking IgG from activating VGCCs in the subject; or blocking VGCCs in the subject are described, as are methods for identifying ALS patients at risk of developing diabetes.

公开(公告)号：US20180125784A1

公开(公告)日：2018-05-10

申请号：US15866146

申请日：2018-01-09

申请人： Tillotts Pharma AG

发明人： Daniel Preisig ,  Maxim Puchkov ,  Joerg Huwyler ,  Felipe José Oliveira Varum ,  Roberto Carlos Bravo Gonzalez

IPC分类号： A61K9/16 ,  A61K9/50 ,  A61K31/4422 ,  A61K31/4178 ,  A61K31/192 ,  A61K31/4164

CPC分类号： A61K9/1611 ,  A61K9/1617 ,  A61K9/50 ,  A61K9/5005 ,  A61K9/5026 ,  A61K31/192 ,  A61K31/4164 ,  A61K31/4178 ,  A61K31/4422

摘要： The present invention relates to a delayed release pharmaceutical formulation for delivering an active agent to the intestine, a method of preparing such formulation and the use of such formulation in the treatment of gastrointestinal disorders.